Abstracts Archive - Page 2326 of 2607 - ACR Meeting Abstracts

Abstract Number: 1621 • 2013 ACR/ARHP Annual Meeting
T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?
Odilia B.J. Corneth¹, Zana Brkic², Cornelia G. van Helden-Meeuwsen³, Radboud J.E.M. Dolhain⁴, Naomi I. Maria³, Sandra M.J. Paulissen⁴, Nadine Davelaar⁵, Jan Piet van Hamburg⁵, Paul L. Van Daele³, Virgil A. Dalm², Martin van Hagen³, Marjan A. Versnel² and Erik Lubberts⁶, ¹Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ⁵Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: A hallmark of systemic autoimmune diseases, such as systemic lupus erythematotsus (SLE), is the increased expression of interferon (IFN) type I inducible genes, the…
Abstract Number: 1622 • 2013 ACR/ARHP Annual Meeting
Deep-Sequencing Reveals Class-Specific Urinary Micrornas In Human Lupus Nephritis
Beatrice Goilav¹, Iddo Z. Ben-Dov², Irene Blanco³, Olivier Loudig⁴, Dawn M. Wahezi⁵ and Chaim Putterman⁶, ¹Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ²Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Epidemiology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatric Rheumatology, Children's Hospital Montefiore, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN), particularly, ISN/RPS class IV LN, is associated with significant morbidity and mortality. microRNAs (miRs) are small, non-coding RNAs that regulate translation.…
Abstract Number: 1582 • 2013 ACR/ARHP Annual Meeting
The Accrual Of Damage In Corticosteroid-Naïve Patients With Systemic Lupus Erythematosus
Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Despite improved survival rates in systemic lupus erythematosus (SLE) over the last 4 decades, organ damage and associated morbidity continues over time. Corticosteroids (CS)…
Abstract Number: 1597 • 2013 ACR/ARHP Annual Meeting
Autonomic Dysfunction In Systemic Lupus Erythematosus Patients With Previous Neuropsychiatric Involvement
Yang Gao, Sheung Wei Li, Lai Heung Chau, Chak Sing Lau and Mo Yin Mok, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Autonomic dysfunction has increasingly been described to be associated with central nervous system (CNS) disorders and has been attributed to damage of the central…
Abstract Number: 1583 • 2013 ACR/ARHP Annual Meeting
Serositis In Systemic Lupus Erythematosus: Prevalence, Recurrence, Treatment and Outcome
Mansour Somaily¹, Dafna D. Gladman², Dominique Ibanez² and Murray B. Urowitz², ¹Medicine, Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Serositis is one of the ACR classification criteria for SLE. Its incidence is variable in studies varying from 12 to 60%. The aim of…
Abstract Number: 1584 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Chronic Isolated Thrombocytopenia In Patients With Systemic Lupus Erythematosus
Amanda J. Steiman¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Past studies have revealed disparity in the clinical significance of thrombocytopenia in systemic lupus erythematosus (SLE), ranging from a benign and incidental finding in…
Abstract Number: 1585 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use Across 52 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials
Ronald F. van Vollenhoven¹, Michelle Petri², Daniel J. Wallace³, David Roth⁴, Charles T. Molta⁴, Anne Hammer⁵, Tom Tang⁵ and April Thompson⁵, ¹The Karolinska Institute, Stockholm, Sweden, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴GlaxoSmithKline, King of Prussia, PA, ⁵GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently receive corticosteroids (CS) as standard therapy. We examined the effects of belimumab on CS dose across 52…
Abstract Number: 1586 • 2013 ACR/ARHP Annual Meeting
Defining Hand Arthritis In Systemic Lupus Erythematosus, From An Ultrasound, Magnetic Resonance Imaging and Antibody Status Perspective
Elisabeth M.A Ball¹, Arthur Grey², Ai Lyn Tan³, Eiji Fukuba⁴, Gunter Steiner⁵, Dennis McGonagle⁶, Aubrey Bell⁷ and Madeleine Rooney⁸, ¹Rheumatology, Queens' University/Musgrave Park Hospital, Belfast, United Kingdom, ²Rheumatology, Musgrave Park Hospital, Belfast, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Radiology, Shimane University, Izuma, Japan, ⁵Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁷Rheumatology Unit, Musgrave Park Hospital, Belfast, United Kingdom, ⁸Medicine, Queens University Belfast, Belfast, United Kingdom
Background/Purpose: Musculoskeletal involvement in systemic lupus erythematosus (SLE) is common but poorly characterised with only a few Magnetic Resonance Imaging (MRI) or ultrasound (US) studies…
Abstract Number: 1587 • 2013 ACR/ARHP Annual Meeting
Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S
Hong Kan¹, Saurabh Nagar¹, Jeetvan Patel¹, Anna Oh², Daniel J. Wallace³ and Charles T. Molta⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²University of California San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, joints, and the nervous system. Standard…
Abstract Number: 1588 • 2013 ACR/ARHP Annual Meeting
Poor Adherence To Medications For Systemic Lupus Erythematosus Among U.S. Medicaid Beneficiaries
Jinoos Yazdany¹, Jun Liu², Graciela S. Alarcon³, Karen H. Costenbader⁴ and Candace H. Feldman⁵, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, Boston, CA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Immunosuppressive and anti-malarial drugs are the cornerstones of treatment for patients with systemic lupus erythematosus (SLE) and have been shown to improve outcomes,…
Abstract Number: 1589 • 2013 ACR/ARHP Annual Meeting
Obesity and Vascular Factors May Play a Role In Persistent Depression Among Individuals With Systemic Lupus Erythematosus
Patricia P. Katz¹, Chris Tonner¹, Laura Trupin¹, Edward H. Yelin² and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, UC San Francisco, San Francisco, CA
Background/Purpose: Depression is commonly reported in systemic lupus erythematosus (SLE), yet information is lacking about long-term patterns of depression. In particular, because depression is thought…
Abstract Number: 1590 • 2013 ACR/ARHP Annual Meeting
A CD8 T Cell-IFN-γ-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE
Dandan Wang¹, Lin Lu², Xuebing Feng³, Xia Li² and Lingyun Sun³, ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Stem cell-based regenerative medicine is a promising approach in tissue reconstruction. Mesenchymal stem cells (MSC) show therapeutic effects on human autoimmune diseases including systemic…
Abstract Number: 1591 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
David Wofsy¹, David A. Isenberg², Daiana Licu³, Yong Li⁴, Claudia Pena Rossi³ and Caroline Gordon⁵, ¹Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Merck Serono S.A., Geneva, Switzerland, ⁴EMD Serono, Rockland, MA, ⁵Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulation factors BLyS and APRIL. Levels of BLyS and APRIL are elevated in patients with SLE.…
Abstract Number: 1592 • 2013 ACR/ARHP Annual Meeting
“Lupus Headache”: Results From a Prospective, International, Inception Cohort Study
John G. Hanly¹, Murray B. Urowitz², Aidan o'Keeffe³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Ann E. Clarke⁸, Sasha Bernatsky⁹, Daniel J. Wallace¹⁰, E.M. Ginzler¹¹, David A. Isenberg¹², Anisur Rahman¹³, Joan T. Merrill¹⁴, Michelle A. Petri¹⁵, Paul R. Fortin¹⁶, D. D. Gladman¹⁷, Barri J. Fessler¹⁸, Graciela S. Alarcon¹⁹, Ian N. Bruce²⁰, Mary Anne Dooley²¹, Kristjan Steinsson²², Munther A. Khamashta²³, Rosalind Ramsey-Goldman²⁴, Susan Manzi²⁵, Gunnar K. Sturfelt²⁶, Ola Nived²⁷, Asad A. Zoma²⁸, R. F. van Vollenhoven²⁹, Manuel Ramos-Casals³⁰, Cynthia Aranow³¹, Meggan Mackay³², Guillermo Ruiz-Irastorza³³, Kenneth C. Kalunian³⁴, S. Sam Lim³⁵, Murat Inanc³⁶, Diane L. Kamen³⁷, Christine Peschken³⁸, Søren Jacobsen³⁹, Chris Theriault⁴⁰, Kara Thompson⁴⁰ and Vernon Farewell³, ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁹Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹³Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ¹⁷Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁸Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁰Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ²¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²²Rheumatology, Landspital Univ Hospital, Reykjavik, Iceland, ²³Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁵Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²⁶Department of Rheumatology, University Hospital Lund, Lund, Sweden, ²⁷Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ²⁸Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²⁹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³⁰Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ³¹The Feinstein Institute, Manhasset, NY, ³²Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ³³Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³⁴UCSD School of Medicine, La Jolla, CA, ³⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³⁶Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Department of Medicine, Medical University of South Carolina, Charleston, SC, ³⁸Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴⁰Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: “Lupus headache” is controversial and is included in validated measures of global SLE disease activity. We examined the frequency and characteristics of “lupus headache”…
Abstract Number: 1594 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, Depression and Anti N-Methyl-D-Aspartate Receptor Antibodies and Anti- Ribosomal P In Systemic Lupus Erythematosus Patients In Argentina
Graciela Gómez¹, Judith Sarano², Maria de los Angeles Gargiulo¹, María Victoria Collado², Lorena Suarez¹, Daniel Fadel³, Alexandra Panopulos⁴ and Marina Khoury⁵, ¹Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ²Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ³Psychiatric, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁴Neurology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁵Research and Teaching, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina
Background/Purpose: Cognitive dysfunction (CD) and depression (D) are common manifestations of neuropsychiatric systemic lupus erythematosus (SLE) and they have been linked to antibodies (abs) like…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].